Vertex inc - Search News

Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

ETF Daily News · 6d

ORG Partners LLC Has $41,000 Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

ORG Partners LLC boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 108.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC).

MarketWatch · 4d

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.

The Motley Fool · 3d

Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?

The FDA is scheduled to make an approval decision for suzetrigine in treating acute pain by Jan. 30, 2025. This non-opioid pain drug targets a multibillion-dollar market. Vertex also has multiple other catalysts on the way in 2025 and over the next few years.

HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws'

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

Yahoo Finance1d

Vertex Pharmaceuticals Incorporated (VRTX)

On Sunday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced multiple program updates, including: In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor ...

Vertex Pharmaceuticals: Strong Future Potential with Key Drug Launches and Underappreciated Opportunities

Jefferies analyst Michael Yee has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

sharewise3d

Vertex's Pain Drug: Big Pharma's Next Major Success?

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

Morningstar3d

Vertex Pharmaceuticals Inc VRTX

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

12d

Vertex turns to Watertown biotech for gene-editing medicines pact

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell disease and transfusion-dependent beta thalassemia.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results